0KHE Stock Overview
Provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Revvity, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$111.22 |
| 52 Week High | US$128.83 |
| 52 Week Low | US$86.51 |
| Beta | 1.06 |
| 11 Month Change | -5.61% |
| 3 Month Change | -8.66% |
| 1 Year Change | 24.20% |
| 33 Year Change | -39.30% |
| 5 Year Change | 22.87% |
| Change since IPO | 34.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0KHE | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 0.9% | -10.6% | 0.8% |
| 1Y | 24.2% | -30.2% | 6.6% |
Return vs Industry: 0KHE exceeded the UK Life Sciences industry which returned -30.2% over the past year.
Return vs Market: 0KHE exceeded the UK Market which returned 6.6% over the past year.
Price Volatility
| 0KHE volatility | |
|---|---|
| 0KHE Average Weekly Movement | 3.8% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0KHE has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0KHE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1937 | 11,500 | Prahlad Singh | www.revvity.com |
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Revvity, Inc. Fundamentals Summary
| 0KHE fundamental statistics | |
|---|---|
| Market cap | US$13.52b |
| Earnings (TTM) | US$258.26m |
| Revenue (TTM) | US$2.72b |
52.4x
P/E Ratio5.0x
P/S RatioIs 0KHE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0KHE income statement (TTM) | |
|---|---|
| Revenue | US$2.72b |
| Cost of Revenue | US$1.21b |
| Gross Profit | US$1.51b |
| Other Expenses | US$1.25b |
| Earnings | US$258.26m |
Last Reported Earnings
Sep 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.12 |
| Gross Margin | 55.37% |
| Net Profit Margin | 9.49% |
| Debt/Equity Ratio | 40.2% |
How did 0KHE perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield13%
Payout RatioDoes 0KHE pay a reliable dividends?
See 0KHE dividend history and benchmarks| Revvity dividend dates | |
|---|---|
| Ex Dividend Date | Jan 17 2025 |
| Dividend Pay Date | Feb 07 2025 |
| Days until Ex dividend | 55 days |
| Days until Dividend pay date | 76 days |
Does 0KHE pay a reliable dividends?
See 0KHE dividend history and benchmarks